Climber_bannerad_300x250_15s

Want your profile here?

Becoming a member is easy!

Climber.com works with you to help you advance your career by putting you directly in front of tens of thousands of recruiters in your field. Just fill out the form below to start your account.

Sign up today!



Jobs_start_here

Recruiters - Try Postings!

Postings.com™ is a must-have for recruiters who want to:

  • Find Qualified Candidates
  • Find Job orders and Post Splits
  • Be Found in Search Engines
  • Implement a Social Sourcing Strategy

Rssmanager/director - 30 years experience

Curriculum Vitae Francis A. Lewandowski 2114 Pyle Street, Wilmington, Delaware 19805 skifra@gmail.com 267-963-8198 Objective: Utilize the breadth of knowledge acquired from almost 30 years of scientific experience in the Pharmaceutical Research & Development Drug Discovery Industry. Titles of positions held include: Analytical Technician, Quality Control Specialist, Scientist, Research Scientist, Senior Scientist, International Sales & Marketing Associate, International Sales & Marketing Manager, Product Development Associate, Product Development Manager, and NASA Scientific Advisory Board Member. Experience: 2013 President & Manager : Domani Healing Studios, (Philadelphia, Pennsylvania 19131) Domani Healing Studios was founded by Frank Lewandowski in 2013 on the primary principle that healing of the body, mind, and spirit can be accomplished by using non-invasive traditional eastern and western bodyworks and therapeutic massage techniques to promote healing. Developed and implemented business and marketing plan to promote new health model and attract clients. Manage company and staff of 3 full time massage therapists. Manage client database to comply with national HIPPA regulations & Pennsylvania State Licensing Board. 2012-2013 Graduate of Lansdale School of Business (LSB) : Lansdale, Pennsylvania, USA & The Spa at LSB Full time student for 6 months (600 hours) to obtain a diploma in massage therapy to qualify for national board certification and licensing. 100 hours of total clinical experience performing over 30 1 hour deep tissue swedish massages on clients. Excellent instructor and customer reviews on professionalism, technique and client health assessment and therapy outline. 1998-2012 Senior Scientist, Jannsen Pharmaceutica, (Spring House, Pennsylvania, USA) Managed the High Throughput Crystallization Screening for all programs within the envelope of Johnson & Johnson and its 100 subsidiary companies. Responsibilities included outsourcing, in-licensing, structure determination, crystal identification, stabilization, and manipulation. Managing a staff of scientists. Data collection in conjunction with the Department of Energy and Synchrotron Radiation Facilities Worldwide. Successfully developed, implemented, and managed a novel automated process for Fragment Based Drug Discovery FBDD. 1998-2004 Research Scientist : 3-Dimensional Pharmaceuticals, Inc. (Exton, Pennsylvania, USA). Mentor: Dr. John Spurlino Managing scientific support staff for crystallization lab Managing several proprietary serine protease, CNS, and oncology crystallization programs. Construct design, expression, and purification of several serine proteases. (italian translation). Native and complexed structure determination through SIR, SeMet-MAD techniques to support medicinal chemistry and the development of potent compounds Cryo-crystallographic data collection: Nonius generator/RAXIS detector and synchrotron radiation (IMCA, CHESS, Brookhaven National Labs). Structural analysis/refinement using XPLOR, CHAIN, O, SnB, DENZO/Scalepack, CCP-4 Suite. Network and system management on various UNIX, Windows/NT or MacOS based systems . Developed a novel high throughput platform for simultaneous experimental setup of 1,000 1-2 µl sitting drop protein crystallization experiments. Patent application submitted and published rapidly screen a set of incomplete factorial solutions using sub-microliter droplets. o Participation in the ISS microgravity flight through the Center for Macromolecular Crystallization at the University of Alabama, Birmingham 2001 – 2008​ Scientific Advisory Board Member NASA & Universities Space Research Association : Development and implementation of an Iterative Biological Crystallization system for the International Space Station. 1996-1998 ​Senior Research Associate : 3-Dimensional Pharmaceuticals, Inc. (Exton, PA) Dr. Roger Bone, re-established company crystallization lab. Initiated internal structural programs producing several hundred protein crystals and structures to support medicinal chemistry and the design of potent inhibitors for all internal programs including serine proteases. Expression, purification, and crystallization of Selino-methionine FGF. Structure determination at 1.9 angstroms using SeMet-MAD phasing at CHESS. 1995-1996 International Sales & Marketing Manager : Protein Solutions, Inc. (Charlottesville, VA) under Sheridan D. Snyder, directing sales and marketing of scientific instrumentation in Europe, Australia, and Eastern U.S. Strong International Government and Corporate Policies skills. Managed over 1,000 clients through Client Management Software System. Researched, developed, and implemented applications for market expansion. Researched core technology to extend product line. Present scientific research at international meetings to promote technological advances. 1994-1995 Eastern Sales & Marketing Manager : Protein Solutions, Inc. (Charlottesville, VA) under Sheridan D. Snyder, managing sales & marketing of scientific instrumentation in Eastern U.S. and Australia. Increasing client volume through application expansion. Restructuring corporate policies to adapt to future markets. Technical writing in application research and development. Discussing current developments at scientific conferences. 1989-1994 Staff Scientist : Chemical and Physical Sciences Department, The DuPont Merck Pharmaceutical Co. (Wilmington, DE), under Dr. Patricia C. Weber, managing crystallography laboratory by overseeing and performing protein purification (HPLC, FPLC), protein crystallization (IMPAX, ICN Micromedics), crystal mounting, x-ray data collection (RAXIS, Elliot GX21, CHESS, Brookhaven National Laboratory), and data processing (RAXIS) on Thrombin and HIV-Pr Inhibitor complexes for structure based drug design. Administrator for IBM, Macintosh, Silicon Graphics Observation Databases with proficiency in DOS, DEC/VMS, UNIX operating environments. Conveying structural results through both formal presentations and interactive discussions to all levels of the research organization. 1989-1994 DuPont Merck Liaison (NASA & University of Alabama) for crystal growth experiments in microgravity aboard the Space Shuttle through collaborative efforts with The Center for Macromolecular Crystallography at the University of Alabama, Marshall Flight Center, and the National Aeronautics Space Association (NASA) 1989- 1994. United States representative for the European Space Agency’s Microgravity Program designing and executing crystallization experiments for upcoming Shuttle missions 1995 - 1996. Interactive participation in development software and hardware for future microgravity experimentation. 1985-1989 Analytical Technician : Polymer Products Department, E.I. DuPont De Nemours & Co. (Wilmington, DE) under Ralph E. Fuller, performing Size Exclusion Chromatography for Molecular Weight Characterization on High Pressure Liquid Chromatography units for materials from Life Sciences, Agriculture, Fiber, and Polymer departments. Execute critical analysis for all DuPont polymer production facilities and DuPont Research and Development groups. Instrumentation development on HPLC utilizing inline viscometry and light scattering. 1984-1985 Quality Control Specialist : Specialty Chemicals Department, Hercules, Inc. (Middletown, DE), assisted in the development, production, analysis, and distribution of photo-polymer resins throughout the United States and Europe Awards: 2005​ Silver Encore Award: Solving the Crystal Structure of MGL and Inhibitor 2003 ​Johnson & Johnson Vice-President’s Research Award for Outstanding Technical Achievement Design and Implementation of the High Throughput Crystallization Platform Process 2000 ​President’s Award: Exceptional Contributions to the PAI 1 Team’s Initial Success 1998 ​President’s Award: Crystallographic Analysis of Thrombin Inhibitors 1997 ​President’s Award: Outstanding contributions to Thrombin Program 1994 ​​DuPont Merck Accomplishment Award: Coordinator for Corporate Hazardous Chemicals 1993 ​​DuPont Merck Performance Award: Outstanding Scientific Contribution Toward Therapeutics 1991​​ DuPont Merck Accomplishment Award: Thrombin Crystallization Optimization ​1989-1994 ​National Aeronautics and Space Administration (NASA) Space Shuttle Program: Crystallization in Microgravity aboard Space Shuttle Flights ( 18 missions total) 1989​ ​ DuPont Merck Accomplishment Award : Crystallization of Isocitrate Lyase in Microgravity Affiliations: 2012-present ​Member of Associated Bodywork & Massage Professionals (ABMP) 1992-present​ Member of the American Crystallographic Association (ACA) Education: 2012-2013: ​Diploma in Massage Therapy, Lansdale School of Business, Lansdale, PA 1982-1983:​ Business Information Systems , Goldey Beacom College, Hockessin, DE 1981-1982:​ Biochemistry Program, University of Delaware, Newark, DE References: Bill Mullen ​​Lansdale School of Business Lansdale PA Dr. Ingrid Deckman ​ Jannsen Pharmaceutica Spring House, PA Jennifer Kirkpatrick​ Jannsen Pharmaceutica Spring House, PA Rose Dandridge​​ Jannsen Pharmaceutica Spring House, PA Published Patent Applications: Patent application number Description Published 20090111711 DEVICE AND METHOD FOR HIGH THROUGHPUT SCREENING OF CRYSTALLIZATION CONDITIONS IN A VAPOR DIFFUSION ENVIRONMENT - A high-density high-throughput microplate and methods for simultaneously screening a plurality of protein crystallization solutions and for producing diffraction quality protein crystals in a vapor-diffusion environment are disclosed. The microplate has defined side-by-side paired chambers of equal size, wherein the side-by-side paired chambers have a maximum volume of about 8 μl, and wherein the paired chambers have a vapor channel, therein providing vapor exchange between the side-by-side paired chambers. The microplate further includes a membrane to seal the surface of the microplate. The microplate is adapted to receive a crystallization solution in one of the side-by-side paired chambers and a protein solution in the other of the side-by-side paired chambers, wherein the protein solution and the crystallization solution interact via a vapor diffusion process, which enables the formation of protein crystals within the chamber that contains the protein solution. 04-30-2009 _________________________________________________________________________________ 20090155815 CRYSTAL STRUCTURE OF THE CARBOXYL TRANSFERASE DOMAIN OF HUMAN ACETYL-COA CARBOXYLASE 2 PROTEIN (ACC2 CT) AND USES THEREOF - A crystallized human ACC2 CT protein as well as a description of the X-ray diffraction pattern of the crystal are disclosed. The diffraction pattern allows the three dimensional structure of human ACC2 CT to be determined at atomic resolution so that ligand binding sites on human ACC2 CT can be identified and the interactions of ligands with human ACC2 CT amino acid residues can be modeled. Models prepared using such maps permit the design of ligands which can function as active agents which include, but are not limited to, those that function as inhibitors of human ACC2 and human ACC1 proteins. 06-18-2009 _______________________________________________________ 20090269784 PROTEIN ENGINEERING OF MONOACYLGLYCEROL LIPASE (MGLL) - A number of soluble engineered forms of MGLL that are suitable for high-throughput screening and protein crystallization, as well as a crystallized form of monoacylglycerol lipase protein (MGLL) and descriptions of the X-ray diffraction patterns are disclosed. The engineered constructs of MGLL permit the expression and purification of protein suitable for crystallography or high-throughput screening and identification of ligands, which can function as active agents to MGLL. The X-ray diffraction patterns allow the three dimensional structure of MGLL to be determined at atomic resolution so that ligand binding sites on MGLL can be identified and the interactions of ligands with MGLL amino acid residues can be modeled. Models prepared using such maps permit the design of ligands which can function as active agents which include, but are not limited to, those that function as inhibitors of MGLL. 10-29-2009 _______________________________________________________ 20090269785 CRYSTAL STRUCTURE OF MONOACYLGLYCEROL LIPASE (MGLL) - A number of soluble engineered forms of MGLL that are suitable for high-throughput screening and protein crystallization, as well as a crystallized form of monoacylglycerol lipase protein (MGLL) and descriptions of the X-ray diffraction patterns are disclosed. The engineered constructs of MGLL permit the expression and purification of protein suitable for crystallography or high-throughput screening and identification of ligands, which can function as active agents to MGLL. The X-ray diffraction patterns allow the three dimensional structure of MGLL to be determined at atomic resolution so that ligand binding sites on MGLL can be identified and the interactions of ligands with MGLL amino acid residues can be modeled. Models prepared using such maps permit the design of ligands which can function as active agents which include, but are not limited to, those that function as inhibitors of MGLL. 10-29-2009 _______________________________________________________ 20100093009 ALTERNATIVE CRYSTAL FORM OF MONOACYLGLYCEROL LIPASE (MGLL) - A number of soluble engineered forms of MGLL that are suitable for high-throughput screening and protein crystallization, as well as a crystallized forms of monoacylglycerol lipase protein (MGLL) and descriptions of the X-ray diffraction patterns are disclosed. The engineered constructs of MGLL permit the expression and purification of protein suitable for crystallography or high-throughput screening and identification of ligands, which can function as active agents to MGLL. The X-ray diffraction patterns allow the three dimensional structure of MGLL to be determined at atomic resolution so that ligand binding sites on MGLL can be identified and the interactions of ligands with MGLL amino acid residues can be modeled. Models prepared using such maps permit the design of ligands which can function as active agents which include, but are not limited to, those that function as inhibitors of MGLL. 04-15-2010 _______________________________________________________ 20110039352 METHODS TO MEASURE DISSOCIATION RATES FOR LIGANDS THAT FORM REVERSIBLE COVALENT BONDS - The crystal structure of the ligand binding domain of ERR-α in complex with a ligand that forms a reversible thioether bond to Cys325 of ERR-α, methods to measure dissociation rates for ligands that form reversible covalent bonds, and methods to design ligands that form reversible covalent bonds for use as modulators of ERR-α activity are disclosed. The crystal structure and methods provide a novel molecular mechanism for modulation of the activity of ERR-α and provide the basis for rational drug design to obtain potent specific ligands for use as modulators of the activity of this new drug target. 02-17-2011 _______________________________________________________ 20110046891 CO-CRYSTALLIZATION OF ERR-alpha WITH A LIGAND THAT FORMS A REVERSIBLE COVALENT BOND - The crystal structure of the ligand binding domain of ERR-α in complex with a ligand that forms a reversible thioether bond to Cys325 of ERR-α, methods to measure dissociation rates for ligands that form reversible covalent bonds, and methods to design ligands that form reversible covalent bonds for use as modulators of ERR-α activity are disclosed. The crystal structure and methods provide a novel molecular mechanism for modulation of the activity of ERR-α and provide the basis for rational drug design to obtain potent specific ligands for use as modulators of the activity of this new drug target. 02-24-2011 Publications: * Crystallization and Structural Analysis of Bullfrog Red Cell L-Subunit Ferritins, J. Trikha, G. S. Waldo, F. A. Lewandowski, H. Ila, E. C. Theil, P. C. Weber, and N. M. Allewell, PROTEINS, vol 18, number 2, 1994 (107 - 118) * Recent Results and New Hardware Developments for Protein Crystal Growth in Microgravity, L. J. DeLucas, F. A. Lewandowski, , and C. E. Bugg, Journal of Crystal Growth 135, 1994 (183-195) * Kinetic and Crystallographic Structures of Thromibin with Ac-(D)Phe-Pro-boroArg-OH and Its Lysine, Amidine, Homolysine, adn Ornithine Analogs, P. C. Weber, S. Lee, F. A. Lewandowski, M. C. Schadt, C.-H. Chang, and C. A. Kettner, Biochemistry, Vol 34, No. 11 (1995) * Binding and Structural Studies of Thrombin Inhibitors Having Systematically Varying P1 Substituents, P. C. Weber, S. L. Lee, F. A. Lewandowski, L. Mersinger, M. C. Schadt, C. H. Chang, and C. A. Kettner (1996) * Molecular Recognition of Cyclic Urea HIV-1 Protease Inhibitors, Paul J. Ala, Frank A. Lewandowski, et al., Journal of Biological Chemistry, Vol. 273, No.20 pp. 12325-12331 * Microplate Thermal Stability Assays for High Throughput Protein Characterization: Applications for Protein Crystallization and Functional Classification, Michael W. Pantoliano, Frank A. Lewandowski, submitted 2000 * Synthesis of Thiophene-2-carboxamidines Containing 2-Amino-thiazoles and their Biological Evaluation as Urokinase Inhibitors, Wilson, KJ, Lewandowski, FA, et. al., Bioorganic & Medicinal Chemistry Letters, 11 (2001) 915-918 * Design and Synthesis of 4,5-Disubstituted-Thiophene-2-Amidines as Potent Urokinase Inhibitors, M. J. Rudolf, Frank A. Lewandowski, et al, submitted 2000 Presentations, Meetings & Posters: ACA annual meetings from 1992 to present The Use of Dynamic Light Scattering in Understanding the Mechanism of Stability, presented at The Annual Conference of Formulation Scientists, Boston MA (1995) A Rational Approach to Protein Crystallography by Use of Dynamic Light Scattering presented at: The 19th Annual Meeting of the Society of Crystallographers in Australia The University of Ballarat, Victoria (1995) The Annual Crystallography Workshop, Cold Spring Harbor Laboratories, NY (1995) Three Dimensional Structures of HIV-1 Protease Complexed with a Novel Non-Peptide Inhibitor based on Cyclic Urea, presented at The 10th International Conference on AIDS, Yokohama, Japan, (1994) Structure Determination of Thrombin:Inhibitor Complexes, Corey Strickland, J. Fevig, R. Galemmo, B. Wells, F. A. Lewandowski, L. Mersinger, C. Kettner, and P. C. Weber, DuPont Merck Summer Intern Program, Wilmington, DE (1994) HIV-1 Research presented at The Annual Meeting of The American Crystallographic Association, Atlanta, GA (1994) Crystal Structure of Boc-(D)Phe-Pro-Arg Thrombin at 2.0 A Resolution. V. L. Nienaber, L. Mersinger, C. Kettner, F. A. Lewandowski, and P. C. Weber ​Mid-Atlantic Protein Crystallography Workshop, Durham, NC (1994) ​American Crystallographic Association Annual Meeting, Atlanta, GA (1994) HIV-1 Research presented at The

Biochemist

About Me

Industry:

Science & Biotech

Occupation:

Biochemist
 

Education level:

Certification

Will Relocate:

Yes

Keywords